Tags :Non-small-cell lung cancer
Targeting LINC01711 in FAP+ cancer-associated fibroblasts overcomes lactate-mediated immunosuppression and enhances anti-PD-1 efficacy in lung adenocarcinoma Summary Targeting LINC01711 in cancer-associated fibroblasts (CAFs) expressing fibroblast activation protein (FAP) shows promise in overcoming immunosuppression in lung Read More
Exploring the metabolic-immune score in advanced NSCLC treated with immunotherapy Summary This research investigates the relationship between a “metabolic-immune score” and outcomes in advanced Non-Small Cell Lung Cancer (NSCLC) patients treated with immunotherapy. The score Read More
First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial Summary A phase 2 trial investigated sacituzumab tirumotecan combined with tagitanlimab as a first-line treatment for advanced non-small-cell lung cancer (NSCLC). The study Read More
Investigating the correlation between IDO1/PD-L1 expression or co-expression and EGFR/KRAS gene mutations in advanced NSCLC Summary This study explores the relationship between IDO1 and PD-L1 expression (both individually and together) and the presence Read More
OH2 oncolytic virus inhibits non-small-cell lung cancer metastasis via β-catenin pathway suppression Summary Oncolytic virus OH2 effectively inhibits non-small-cell lung cancer (NSCLC) metastasis. Researchers demonstrated that OH2 suppresses the Wnt/β-catenin signaling pathway, a key Read More
Single-cell spatial analysis with Xenium reveals anti-tumour responses of CXCL13 + T and CXCL9+ cells after radiotherapy combined with anti-PD-L1 therapy Summary A study using single-cell spatial analysis with the Xenium platform investigated the effects of Read More
Tumor aneuploidy as a prognostic and predictive biomarker in immune checkpoint blockade Summary Tumor aneuploidy, an abnormal chromosome number, is increasingly recognized as a crucial factor influencing cancer progression and response to immunotherapy, particularly immune Read More
